Workflow
百时美施贵宝(BMY)
icon
搜索文档
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc. (Nasdaq – AVRO), California BanCorp (Nasdaq – CALB), Exro Technologies Inc. (OTC – EXROF), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
Newsfilter· 2024-01-31 00:13
BALA CYNWYD, Pa., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. AVROBIO, Inc. (Nasdaq – AVRO) Under the terms of the agreement, AVROBIO will merge with Tectonic Therapeutic, Inc. ("Tectonic"). In the deal, pre-Merger AVROBIO shareholders ...
Wall Street's Insights Into Key Metrics Ahead of Bristol Myers (BMY) Q4 Earnings
Zacks Investment Research· 2024-01-30 23:21
Wall Street analysts forecast that Bristol Myers Squibb (BMY) will report quarterly earnings of $1.56 per share in its upcoming release, pointing to a year-over-year decline of 14.3%. It is anticipated that revenues will amount to $11.11 billion, exhibiting a decline of 2.6% compared to the year-ago quarter.The consensus EPS estimate for the quarter has been revised 11.2% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their i ...
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
Newsfilter· 2024-01-30 22:15
PALM BEACH, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Recent reports show that the Multiple myeloma Diagnostic market will continue to grow in the next several years. Multiple myeloma is a type of plasma cell cancer. Normal plasma cells are recognized as an important component of the immune system. The immune system is made up of various types of cells that work together to fight infections and other diseases. The main types of white blood cells in the immune system are lympho ...
Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Businesswire· 2024-01-30 19:59
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced three regulatory acceptances from the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) for Breyanzi® (lisocabtagene maraleucel). In the U.S., the FDA has accepted the company’s two supplemental Biologics License Applications (sBLA) for Breyanzi to expand into new indications to include the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) and rela ...
Bristol Myers Squibb (BMY) Increases Yet Falls Behind Market: What Investors Need to Know
Zacks Investment Research· 2024-01-30 07:46
The latest trading session saw Bristol Myers Squibb (BMY) ending at $49.87, denoting a +0.34% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily gain of 0.76%. On the other hand, the Dow registered a gain of 0.59%, and the technology-centric Nasdaq increased by 1.12%.Coming into today, shares of the biopharmaceutical company had lost 3.14% in the past month. In that same time, the Medical sector gained 1.57%, while the S&P 500 gained 2.5%.The investment community w ...
Subcutaneous Nivolumab (nivolumab and hyaluronidase) Shows Noninferiority Compared to Intravenous Opdivo (nivolumab) in Advanced or Metastatic Clear Cell Renal Cell Carcinoma in CheckMate -67T Trial
Businesswire· 2024-01-27 23:00
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the first disclosure of data from the Phase 3 CheckMate -67T trial, evaluating the subcutaneous formulation of Opdivo (nivolumab) co-formulated with Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20) (herein referred to as “subcutaneous nivolumab”) compared to intravenous (IV) Opdivo in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior systemic therapy, demonstr ...
3 Healthcare Stocks at 52-Week Lows: Buy or Bye?
InvestorPlace· 2024-01-27 01:01
Healthcare stocks trudged through what was a terrible 2023 for the sector. While the S&P 500 rose by 24% during 2023, the healthcare sector managed paltry returns of 0.3%. Yet, hope springs eternal, particularly within the stock market, and investors are increasingly vocalizing their expectations for a 2024 rebound. Share prices throughout the sector remain muted, providing many targets for those hoping to capitalize on what they see as overly low valuations.Bargain hunters will have many choices throughout ...
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
Businesswire· 2024-01-26 20:13
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization approval of Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibod ...
What You Need to Know Ahead of Bristol-Myers (BMY) Q4 Earnings
Zacks Investment Research· 2024-01-26 00:36
Bristol-Myers Squibb Company (BMY) is scheduled to report fourth-quarter 2023 results on Feb 2, before market open.The company’s shares have lost 20.7% in the past six months compared with the industry's 0.3% growth.Image Source: Zacks Investment ResearchBristol-Myers beat earnings estimates in three of the last four quarters and missed once, the average surprise being 2.89%. In the previously reported quarter, the company beat estimates by 13.64%.Factors at PlayTotal revenues in the fourth quarter are like ...
Dividend Harvesting Portfolio Week 151: $15,100 Allocated, $1,331.13 In Projected Dividends
Seeking Alpha· 2024-01-25 22:00
PM Images It was another good week in the markets as the S&P 500 increased by 1.52% and the Nasdaq jumped 2.53%. The University of Michigan's consumer sentiment report increased to 78.8, which is the highest level since July of 2021. Technology led the markets higher as Taiwan Semiconductor (TSMC) announced a better-than-expected forecast that fueled the narrative around artificial intelligence. The U.S. economic data will be front and center next week as everyone will be looking for Q4 GDP growth estim ...